LCL161

For research use only.

Catalog No.S7009

23 publications

LCL161 Chemical Structure

CAS No. 1005342-46-0

LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).

Selleck's LCL161 has been cited by 23 publications

Purity & Quality Control

Choose Selective IAP Inhibitors

Biological Activity

Description LCL-161, a small molecule second mitochondrial activator of caspase (SMAC) mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
Targets
cIAP [1] XIAP [1]
In vitro

LCL161 binds to inhibitors of apoptosis proteins (IAPs) with high affinity and initiates the destruction of cIAP1 and cIAP2, which further induces apoptosis via caspase activation. LCL161 modestly inhibits the growth of FLT3-ITD-expressing cells when administered alone, with an IC50 ranging from ~0.5 μM (Ba/F3-FLT3-ITD cells) to ~4 μM (MOLM13-luc+ cells). The potency of LCL161 against the D835Y mutant is observed to be considerably higher, with an IC50 of ~50 nM when tested against Ba/F3-D835Y cells. Treatment of MOLM13-luc+ cells with a combination of LCL161 and PKC412 leads to significantly more killing of cells than either agent alone, with Calcusyn combination indices suggestive of synergy. PKC412 and LCL161 induces apoptosis of MOLM13-luc+ cells. The combination of PKC412 and LCL161 leads to a higher induction of apoptosis than either agent alone. LCL161 is able to override stromal-mediated rescue of mutant FLT3-expressing cells through positive combination with PKC412. LCL161 inhibits the growth of Ba/F3.p210 cells with an IC50 of ~100 nM. The combination of LCL161 and the ABL inhibitor, imatinib, is observed to be synergistic against BCR-ABL-expressing cells. LCL161 also has demonstrated activity against drug-resistant cells expressing point mutations in the target proteins. LCL161 at 1000 nM is able to mostly or completely kill Ba/F3-derived cell lines conferring resistance to PKC412, which express FLT3-ITD harboring point mutations in the ATP-binding pocket of FLT3. LCL161 also shows activity at concentrations ranging from 100 to 1000 nM against Ba/F3 cells expressing various imatinib- and nilotinib-resistant BCR-ABL point mutations. [1] LCL161 is evaluated against the 23 cell lines in the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr. LCL161 achieves 50% growth inhibition against only 3 of the 23 tested PPTP cell lines under concentration of 10 μM. The three cell lines includes two T-cell ALL cell lines (COG-LL-317 and CCRF-CEM) and an anaplastic large cell lymphoma cell line (Karpas-299), with CCRF-CEM and Karpas-299 showing the lowest relative IC50 values (0.25 and 1.6 μM, respectively). [2] LCL161shows immunomodulatory properties on human immune subsets. T lymphocytes treated with LCL161 demonstrates significantly enhanced cytokine secretion upon activation, with little effect on CD4 and CD8 T-cell survival or proliferation. LCL161 treatment of peripheral blood mononuclear cells significantly enhances priming of naïve T cells with synthetic peptides in vitro. Myeloid dendritic cells undergoes phenotypic maturation upon LCL161 and demonstrates a reduced capacity to cross-present a tumor antigen-based vaccine. These effects are potentially mediated through an observed activation of the canonical and non-canonical NF-κB pathways, following LCL161 with a resulting upregulation of anti-apoptotic molecules. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LOX MVrGeY5kfGmxbjDhd5NigQ>? MlroNVAxKG2pL3vn NVTReHVKQCCqcoO= NWXhSYdWWG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[0mDUEGg[IVoemGmYYTpc44hcW5iaIXtZY4hVE:[IHPlcIx{KHinbn;ndoFnfGWmIHnuJI1wfXOnIHH0JFExOCCvZz;r[{wheG9iYX\0[ZIhQCCqcoOgZpkhX2W|dHXyckBjdG:2dHnu[{BidmGueYPpdy=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
LOX M3r5PGZ2dmO2aX;uJIF{e2G7 MVi4JIhzew>? MnPpVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ4F{eGG|ZTCzM|ch[WO2aY\heIlwdiCrbjDoeY1idiCOT2igZ4VtdHNieHXuc4dz[W[2ZXSgbY4hdW:3c3WgZYZ1\XJiODDodpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7 NEnwWoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC4N|c5Oid-MkSwPFM4QDJ:L3G+
MDA-MB-231 MVXGeY5kfGmxbjDhd5NigQ>? MkLCNk42KHSxIEGwJJVO NHiwXGUyQSCqcoO= NITEdndDcW6maX7nJIFn\mmwaYT5JJRwKGOLQWCxJGJKWjNiZH;tZYlvKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gWG5H[WyyaHGgcIV3\WxiYYSgNk42KHSxIEGwJJVOKGGodHXyJFE6KGi{czDifUBGVEmVQR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
BxPC3 MX3GeY5kfGmxbjDhd5NigQ>? NF3GXIM{NjNidV2= MUW1JIRigXN? MV3Qc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCfHBEOyClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
HCT15 M3rCPGZ2dmO2aX;uJIF{e2G7 M1PQWlMvOyC3TR?= NF61VFM2KGSjeYO= MYDQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> M2jPT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEizO|gzLz5{NEC4N|c5OjxxYU6=
SW620 M1nBfmZ2dmO2aX;uJIF{e2G7 M2ryTFEvOSC3TR?= Ml\5OUBl[Xm| MUDQc5RmdnSrYYTpc44hd2ZiY3;uZZR2dXWvYXKtbY5lfWOnZDDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{BifCBzLkGgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
SW620 NFzUN21HfW6ldHnvckBie3OjeR?= M{TDPFMvOyC3TR?= NVqyWYpEPSCmYYnz M3;qZnBwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNYPjJyIHPlcIx{KGG2IEOuN{B2VSCjZoTldkA2KGSjeYOgZpkhVVSVIHHzd4F6 NXv6OmdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
LOX Ml\JSpVv[3Srb36gZZN{[Xl? NH3yOZo{NjNidV2= NXTReZVCOyCmYYnz MmGzVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG9ZKGOnbHzzJIF1KDNwMzD1UUBi\nSncjCzJIRigXNiYomgUXRUKGG|c3H5 NUjIZoRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPFM4QDJpPkK0NFg{Pzh{PD;hQi=>
LS180 Mo\BSpVv[3Srb36gZZN{[Xl? MmnHN{4{KHWP MnzmOUBl[Xm| MojrVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHMyQDBiY3XscJMh[XRiMz6zJJVOKGGodHXyJFUh\GG7czDifUBOXFNiYYPzZZk> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
H460 MX;GeY5kfGmxbjDhd5NigQ>? MUWzMlMhfU1? MoO2OUBl[Xm| MnLSVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BifCB|LkOgeW0h[W[2ZYKgOUBl[Xm|IHL5JG1VWyCjc4PhfS=> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB6M{e4Nkc,OjRyOEO3PFI9N2F-
LOX MUfGeY5kfGmxbjDhd5NigQ>? M3rPeVExOCCvZz;r[y=> MlK1PEBpenN? MnvVVIxie22jIHPvcoNmdnS{YYTpc44hcW5iboXk[UBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKEyRWDDj[YxteyCjdDCxNFAhdWdxa3esJJBwKG2nYYP1doVlKGG2IEigbJJ{NCCFcDC9JFMvOyEQvF2u MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
SW620 NXLRbGdGTnWwY4Tpc44h[XO|YYm= NIjZNok2KGSjeYO= MYfJcoR2[3Srb36gc4Yhe2Wwc3n0bZpifGmxbjDv[kBpfW2jbjDTW|YzOCClZXzsd{B1dyClb37heJVufW2jYj3pcoR2[2WmIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB3IHThfZMh[nliTWTTJIF{e2G7LDDFR|kxKD1iNj62OkDPxE1w Mnj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
LOX NX7pO2IxTnWwY4Tpc44h[XO|YYm= NI[1UFYyODBibXevb4c> Mn;XPEBpenN? MknXSJJ2\yC3cIThb4UhcW5idIXtc5Ihd2ZiboXk[UBud3W|ZTD4[Y5w\3KjZoTl[EB4cXSqIHj1cYFvKEyRWDDj[YxteyCjdDCxNFAhdWdxa3esJJBwKG2nYYP1doVlKGG2IEigbJJ{NCCGcoXnJJVxfGGtZTC9JFE5NjRizszNMi=> NVvwVm5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
SW620 NGDKfW1HfW6ldHnvckBie3OjeR?= NVPmNG9GOi53IIXN NXv3ZZN[PSCmYYnz MVzJcoR2[3Srb36gc4Yhe2Wwc3n0bZpifGmxbjDv[kBpfW2jbjDTW|YzOCClZXzsd{B1dyClb37heJVufW2jYj3pcoR2[2WmIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= M3vUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
LOX MWrGeY5kfGmxbjDhd5NigQ>? M{jB[|ExOCCvZz;r[y=> MoC1PEBpenN? M3rteGlvKH[rdn:gbY5pcWKrdHnvckBw\iC[SVHQJGJKWjJiZH;tZYlvKGmwIHj1cYFvKEyRWDDj[YxteyC6ZX7v[5Ji\nSnZDDpckBvfWSnIH3veZNmKGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iClb37heJVufW2jYj3pcoR2[2WmIHPhd5Bie2ViMz:3JIFkfGm4aYT5JIF1KDFyMDDt[{9s\yxicH:gZYZ1\XJiODDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
LOX MV3GeY5kfGmxbjDhd5NigQ>? M3m5OVExOCCvZz;r[y=> MlftPEBpenN? NULGRXp3UW5idnn2c{BqdmirYnn0bY9vKG:oIGjJRXAhSkmUMjDkc41icW5iaX6gbJVu[W5iTF;YJINmdGy|IIjlco9oemGodHXkJIlvKG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[2G|cHHz[UA{NzdiYXP0bZZqfHliYYSgNVAxKG2pL3vnMEBxdyCjZoTldkA5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? M{PLdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
MDA-MB-231 MV;GeY5kfGmxbjDhd5NigQ>? NXvMdmoxOC5|NzD0c{A{NjNidV2= MmrsNVkhcHK| M{HTXmlvcGmkaYTpc44hd2ZiY1nBVFEwOiCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBVVk[jbIDoZUBt\X[nbDDheEAxNjN5IITvJFMvOyC3TTDh[pRmeiBzOTDodpMh[nliRVzJV2E> NIrwWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5N|k1OCd-MkSwPVM6PDB:L3G+
CHL1 NV7xcVZ6TnWwY4Tpc44h[XO|YYm= MUCwMlQhfG9iMUCgeW0> NHXBUZMzQCCqcoO= NEO2UllKdmirYnn0bY9vKG:oIHPJRXAyKGmwIHj1cYFvKEOKTEGgZ4VtdHNiYYSgNE41KHSxIEGwJJVOKGGodHXyJFI5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{m0NEc,OjRyOUO5OFA9N2F-
SKMES1 NX7NRXFHTnWwY4Tpc44h[XO|YYm= M3XLT|IvPSC3TR?= MVu1JIRigXN? MnXJVI91\W62aXH0bY9vKG:oIHPvcoF1fW23bXHiMYlv\HWlZXSgZZBweHSxc3nzJIlvKGi3bXHuJHNMVUWVMTDj[YxteyCjdDCyMlUhfU1iYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5NigQ>? MnzKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
Capan1 MVvGeY5kfGmxbjDhd5NigQ>? Mnf3Nk42KHWP MYC1JIRigXN? NXftSIN7WG:2ZX70bYF1cW:wIH;mJINwdmG2dX31cYFjNWmwZIXj[YQh[XCxcITvd4l{KGmwIHj1cYFvKEOjcHHuNUBk\WyuczDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= NXy5[HNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM6PDBpPkK0NFk{QTRyPD;hQi=>
AGS M2DHfWZ2dmO2aX;uJIF{e2G7 MnjnNk42KHWP M2HIfFUh\GG7cx?= M3T6T2lv\HWldHnvckBw\iC|ZX7zbZRqgmG2aX;uJI9nKGi3bXHuJGFIWyClZXzsd{B1dyClb37heJVufW2jYj3pcoR2[2WmIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAzNjVidV2gZYZ1\XJiNTDkZZl{KGK7IF3UV{Bie3OjeR?= Mn;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO5OFAoRjJ2MEmzPVQxRC:jPh?=
U118MG MX7GeY5kfGmxbjDhd5NigQ>? MYqyMlUhfU1? MVe1JIRigXN? M1rKO3BwfGWwdHnheIlwdiCxZjDjc45ifHWvdX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCqdX3hckBWOTF6TVegZ4VtdHNiYYSgNk42KHWPIHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[Xl? M2i1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
PC3 M2DQSGZ2dmO2aX;uJIF{e2G7 MXyyMlUhfU1? M4S1SVUh\GG7cx?= NETNXmNKdmS3Y4Tpc44hd2Zic3Xud4l1cXqjdHnvckBw\iCqdX3hckBRSzNiY3XscJMhfG9iY3;uZZR2dXWvYXKtbY5lfWOnZDDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZZQhOi53IIXNJIFnfGW{IEWg[IF6eyCkeTDNWHMh[XO|YYm= M1XK[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEmzPVQxLz5{NEC5N|k1ODxxYU6=
CCRF-CEM MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NEXVOHBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDVmYuS0WPIHPlcIx{NCCJSUWwJF0hOC5{NTFOwG0v Mn7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{W1NlYoRjJ6NEO1OVI3RC:jPh?=
MDA-MB-231 M1fDbGZ2dmO2aX;uJIF{e2G7 NGHYcFYzKGi{cx?= Mk[zTY5lfWO2aX;uJI9nKGOLQWCxJIRm\3KjZHH0bY9vKGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[W[2ZYKgNkBpenNuIFXDOVAhRSByLkCwNFQh|ryPLh?= MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUKzNVcoRjJ6NEmyN|E4RC:jPh?=
MDA-MB-231 NITnPYhEgXSxdH;4bYNqfHliYYPzZZk> MXW3NkBpenN? MkXFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCHQ{WwJF0hOC5yMEe4JO69VS5? M3;5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEmyN|E4Lz5{OES5NlMyPzxxYU6=
HEK293 NY\NSJpTTnWwY4Tpc44h[XO|YYm= NWXFOml{OiCqcoO= MWrJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIF\MRWcufGGpZ3XkJHhKSVBiKIXub45wf25ib4Lp[4lvMSCrboTldoFkfGmxbjD3bZRpKG[3bHygcIVv\3SqIIXueIFo\2WmIHPhd5Bie2VvOTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDJiaILzJIJ6KGmvbYXuc5Bz\WOrcHn0ZZRqd25iYYPzZZktKEWFNUCgQUAxNjB|NTFOwG0v MojpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OUKzNVcoRjJ6NEmyN|E4RC:jPh?=
MDA-MB-231 M2W1U2FvfGm2dX3vdkBie3OjeR?= MoThN|AhdWdxa3e= MYeyOEBl[Xm| NFvTZ|RCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IIjlco9oemGodHXkJIlvKEKjbHKvZ{BUS0mGIH3veZNmKGG|c3Xzd4VlKGG|IIT1cY9zKGe{b4f0bEBqdmirYnn0bY9vKGG2IEOwJI1oN2upIHHkcYlvcXO2ZYLl[EB3cWFib4LhcEBo[X[jZ3Wg[o9zKDJ2IHThfZM> M4W1[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEmyN|E4Lz5{OES5NlMyPzxxYU6=
MDA-MB-231 MWDGeY5kfGmxbjDhd5NigQ>? M2i1O|IhcHK| MlXYTY5lfWO2aX;uJI9nKGmwdILhZ4VtdHWuYYKgZ2lCWDFiZHXndoFl[XSrb36gbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB{IHjyd{whUUN3MDC9JFAvODByNDFOwG0v MoXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByOUG2NFAoRjNyMEmxOlAxRC:jPh?=
MDA-MB-231 MlOwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWG3NkBpenN? MkOyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGGodHXyJFczKGi{czDifUBCdGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFAvODB5ODFOwG0v MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7MU[wNEc,OzByOUG2NFA9N2F-
HEK293 MkTYSpVv[3Srb36gZZN{[Xl? M3nJdFIhcHK| MnPNTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDGUGFINXSjZ3fl[EBZUUGSIDj1cotvd3ewIH;ybYdqdiliaX70[ZJi[3Srb36ge4l1cCCodXzsJIxmdme2aDD1cpRi\2enZDDjZZNx[XOnLUmg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDh[pRmeiB{IHjyd{BjgSCrbX31co9xemWlaYDpeIF1cW:wIHHzd4F6NCCLQ{WwJF0hOC5yM{Wg{txONg>? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7MU[wNEc,OzByOUG2NFA9N2F-
SKOV3 NUL5Z3pUSXCxcITvd4l{KGG|c3H5 NFyzN4I1QCCqcoO= NHzvUmRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIGPLU3Y{KGOnbHzzJIF{e2W|c3XkJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGodHXyJFQ5KGi{czDifUBKdmO3Q4n0[UBUOyCuaY\lMYNmdGxiYX7hcJl{cXNuIFXDOVAhRSByLkCwNUDPxE1w MnXQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzFyOUWzPFYoRjNzMEm1N|g3RC:jPh?=
SKOV3 NXzO[5pqSXCxcITvd4l{KGG|c3H5 MmX6NlQhcHK| NWHxXFFjUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT29XOyClZXzsd{Bie3Onc4Pl[EBk[XOyYYPlMVMh[WO2aY\heIlwdiCjZoTldkAzPCCqcoOgZpkhUW6ldVP5eIUhWzNibHn2[U1k\WyuIHHuZYx6e2m|LDDFR|UxKD1iMD6wNFMh|ryPLh?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB7NUO4Okc,OzFyOUWzPFY9N2F-
BL21(DE3) NX:zboF2TnWwY4Tpc44h[XO|YYm= MoXqNkBpenN? M3q0cmRqe3CuYXPlcYVvfCCxZjDibY91cW67bHH0[YQhSV[SRjDmdo9uKE5vdHXycYlv[WxiSHnzJJRi\2enZDDy[YNwdWKrbnHueEBpfW2jbjDYTWFRNUKLUkOg[I9u[WmwIDiyOVMhfG9iM{S3JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxLGRGOyliY3XscJMhcW6ldXLheIVlKG[xcjCyJIhzeyCkeTDESWxHUUFuIFnDOVAhRSByLkC0PEDPxE1w M{HUS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
BL21(DE3) NU[5UFZHTnWwY4Tpc44h[XO|YYm= M3[wVlghcHK| NIrib3FFcXOybHHj[Y1mdnRib3[gZolwfGmweXzheIVlKEGYUF[g[pJwdSCQLYTldo1qdmGuIFjpd{B1[WepZXSgdoVkd22kaX7hcpQhcHWvYX6gXGlCWC2ESWKzJIRwdWGrbjCoNlU{KHSxIEO0O{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUhFTTNrIHPlcIx{KGmwY4XiZZRm\CCob4KgPEBpenNiYomgSGVNTkmDLDDJR|UxKD1iMD6wOVMh|ryPLh?= M4qxdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEm1N|g3Lz5|MUC5OVM5PjxxYU6=
A549 M{jaRmZ2dmO2aX;uJIF{e2G7 M{LvbVEhfU1? NWPjfJlGOyCqcoO= MVPJcoR2[3Srb36gc4Yh[0mDUEKg[IVoemGmYYTpc44hcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[0mDUEKgdJJwfGWrbjDs[ZZmdCCjdDCxJJVOKGmwY4XiZZRm\CCob4KgN{BpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTV3MEG1OUc,OzF3NUCxOVU9N2F-
SK-MEL-28 NYXRSmxpTnWwY4Tpc44h[XO|YYm= NVXmSIZ{OSC3TR?= NY\s[lZrOyCqcoO= M2roTWlv\HWldHnvckBw\iClSVHQNUBl\We{YXTheIlwdiCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINKSVBzIIDyc5RmcW5ibHX2[Ywh[XRiMTD1UUBqdmO3YnH0[YQh\m:{IEOgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> M4LQcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzNUWwNVU2Lz5|MUW1NFE2PTxxYU6=
SK-MEL-28 MXTGeY5kfGmxbjDhd5NigQ>? MUCxJJVO NH24cFQ{KGi{cx?= MYrJcoR2[3Srb36gc4Yh[0mDUEKg[IVoemGmYYTpc44hcW5iaIXtZY4hW0tvTVXMMVI5KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDjTWFROiCycn;0[YlvKGyndnXsJIF1KDFidV2gbY5kfWKjdHXkJIZweiB|IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NFXKTWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUW1NFE2PSd-M{G1OVAyPTV:L3G+
HEK293T MmTpSpVv[3Srb36gZZN{[Xl? M1PYNlExKHWP NGnE[Ww3KGi{cx?= NHq1fmlEd3[jbHXueEBjcW6maX7nJIFn\mmwaYT5JJRwKEiDLVLJVlMh\G:vYXnuJI9nKFiLQWCgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCkYX7kJIlvfGWwc3n0fUBifCBzMDD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MmTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF3NUCxOVUoRjNzNUWwNVU2RC:jPh?=
A549 NHOzO5FHfW6ldHnvckBie3OjeR?= NXSzco15OSC3TR?= NVK3[m9OOyCqcoO= NHjNN4dKdmS3Y4Tpc44hd2ZiY1nBVFEh\GWpcnHkZZRqd25iaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY1nBVFEheHKxdHXpckBt\X[nbDDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOyCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NGjrfYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUW1NFE2PSd-M{G1OVAyPTV:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cIAP1 / cIAP2 / XIAP / surivivin ; 

PubMed: 27737687     


A549 and H460 cells were treated for 48 h with 0-20 μM LCL161. The protein levels of cIAP1, cIAP2, XIAP and survivin were assessed by western blotting. β-actin was used as a loading control. The bar graphs represent the mean ± SD of different proteins/β-actin; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
Growth inhibition assay
Cell viability; 

PubMed: 27737687     


Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c) or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001

27737687
In vivo LCL161 significantly enhances the ability of PKC412 to inhibit the growth of Ba/F3-FLT3-ITD-luc+ cells in vivo. LCL161 is also shown to positively combine with the standard chemotherapeutic agents, Ara-c and doxorubicin, against FLT3-ITD-expressing cells and against D835Y-expressing cells. There is an additive effect achieved by combining both Nilotinib and LCL161 in suppressing leukemia growth. LCL161 (100 mg/kg) enhances in vivo effects of high-moderate doses of nilotinib (100 mg/kg) on leukemia burden in mice. [1] CL161 is tested against the Pediatric Preclinical Testing Program (PPTP) in vivo panels (30 or 75 mg/kg [solid tumors] or 100 mg/kg [ALL]) administered orally twice in a week. LCL161 induces significant differences in EFS distribution in approximately one-third of solid tumor xenografts (osteosarcoma and glioblastoma), but not in ALL xenografts. No objective tumor responses are observed. In vivo LCL161 demonstrates limited single agent activity against the pediatric preclinical models studied. [2]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Human T-cell ALL cell lines COG-LL-317
  • Concentrations: ~10 μM
  • Incubation Time: 96 hours
  • Method:

    In vitro testing is performed using DIMSCAN


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (199.74 mM)
Water Insoluble
Ethanol '20 mg/mL warmed

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 500.63
Formula

C26H33FN4O3S

CAS No. 1005342-46-0
Storage powder
in solvent
Synonyms N/A
Smiles CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03111992 Completed Drug: PDR001|Drug: CJM112|Drug: LCL161 Multiple Myeloma Novartis Pharmaceuticals|Novartis December 18 2017 Phase 1
NCT01934634 Unknown status Drug: LCL161|Drug: Gemcitabine|Drug: nab-Paclitaxel Metastatic Pancreatic Cancer US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research LLC March 2014 Phase 1
NCT01968915 Completed Drug: LCL161|Drug: Paclitaxel Neoplasms Novartis Pharmaceuticals|Novartis November 2013 Phase 1
NCT01617668 Completed Drug: LCL161|Drug: paclitaxel Breast Cancer Novartis Pharmaceuticals|Novartis August 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IAP Signaling Pathway Map

Tags: buy LCL161 | LCL161 supplier | purchase LCL161 | LCL161 cost | LCL161 manufacturer | order LCL161 | LCL161 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID